Literature DB >> 15337482

Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

Johan Vansteenkiste1, Barbara M Fischer, Christophe Dooms, Jann Mortensen.   

Abstract

Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [(18)F]FDG uptake on PET has independent prognostic value in newly diagnosed non-small-cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [(18)F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [(18)F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [(18)F]FDG-PET over CT in the correct identification of recurrent lung cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15337482     DOI： 10.1016/S1470-2045(04)01564-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


  40 in total

1.  Measuring tumor aggressiveness and targeting metastatic lesions with fluorescent pHLIP.

Authors:  Yana K Reshetnyak; Lan Yao; Sida Zheng; Sergey Kuznetsov; Donald M Engelman; Oleg A Andreev
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

2.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

Review 3.  Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy.

Authors:  David A Mankoff; Finbarr O'Sullivan; William E Barlow; Kenneth A Krohn
Journal:  Acad Radiol       Date:  2007-04       Impact factor: 3.173

Review 4.  PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.

Authors:  Filippo Lococo; Alfredo Cesario; Massimiliano Paci; Angelina Filice; Annibale Versari; Cristian Rapicetta; Tommaso Ricchetti; Giorgio Sgarbi; Marco Alifano; Alberto Cavazza; Giorgio Treglia
Journal:  Tumour Biol       Date:  2014-05-22

5.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

6.  Higher-order singular value decomposition-based lung parcellation for breathing motion management.

Authors:  Samadrita Roy Chowdhury; Joyita Dutta
Journal:  J Med Imaging (Bellingham)       Date:  2019-05-03

7.  Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements.

Authors:  Mahsa Eskian; Abass Alavi; MirHojjat Khorasanizadeh; Benjamin L Viglianti; Hans Jacobsson; Tara D Barwick; Alipasha Meysamie; Sun K Yi; Shingo Iwano; Bohdan Bybel; Federico Caobelli; Filippo Lococo; Joaquim Gea; Antonio Sancho-Muñoz; Jukka Schildt; Ebru Tatcı; Constantin Lapa; Georgia Keramida; Michael Peters; Raef R Boktor; Joemon John; Alexander G Pitman; Tomasz Mazurek; Nima Rezaei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-22       Impact factor: 9.236

8.  Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.

Authors:  Christos Sachpekidis; Christian Thieke; Vasileios Askoxylakis; Nils H Nicolay; Peter E Huber; Michael Thomas; Georgia Dimitrakopoulou; Juergen Debus; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

9.  Molecular imaging of solid tumors: exploiting the potential.

Authors:  Wim J G Oyen; Winette T A van der Graaf
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

10.  Decreased 3D observer variation with matched CT-MRI, for target delineation in Nasopharynx cancer.

Authors:  Coen R N Rasch; Roel J H M Steenbakkers; Isabelle Fitton; Joop C Duppen; Peter J C M Nowak; Frank A Pameijer; Avraham Eisbruch; Johannes H A M Kaanders; Frank Paulsen; Marcel van Herk
Journal:  Radiat Oncol       Date:  2010-03-15       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.